This guide focuses on two Shockwave technologies: Radial Pressure Wave (EPAT® or Extracorporeal Pulse Activation Technology) and Focused Shockwave (ESWT or Extracorporeal Shockwave Therapy). Together, these technologies can support multimodal, non-invasive treatment strategies across musculoskeletal and soft tissue applications.
Shockwave is supported by decades of research and earns an 80%+ patient satisfaction rate, but selecting the right device for your practice is not always straightforward. A strong buying process should help you look beyond the initial purchase and understand what it will take to achieve clinical proficiency, patient impact, and long-term ROI.
This guide walks through the key questions medical professionals should ask when evaluating Shockwave technology, choosing the right manufacturer and distribution partner, and building the foundation for long-term success.
New to Shockwave? It may help to start with a foundational overview of how Shockwave therapy works, what it is used for, and how it supports tissue repair and regeneration.
For medical professionals evaluating Shockwave, the earliest questions should focus on the bigger picture: what you are investing in, how the technology will fit into your continuum of care, and what it will take to use it successfully over time.
When practices focus too narrowly on finding the lowest-cost option or comparing technical details in isolation, they risk making a purchase that never reaches its full clinical or economic potential.
A stronger evaluation looks beyond initial purchase price alone to consider what will help your team use Shockwave consistently to improve patient outcomes and drive ROI from your investment over the long term.
The questions below are a great place to start.
Each of these questions reflects a real implementation challenge that practices need to solve in order to get the most out of Shockwave. A thoughtful, proactive provider should not only be prepared to answer them clearly, but should also have proven strategies, resources, and support systems already in place.
Certain early questions can derail your Shockwave evaluation if they become the center of the decision-making process:
These are not irresponsible questions in themselves. Cost, purchasing options, and total investment all matter.
The issue is that leading with these questions can shift the evaluation away from what will actually determine whether Shockwave succeeds in your practice — and whether you are buying the right device to deliver the best possible medical treatment to your patients.
The real risk is ending up with a marginally cheaper device that your team is not prepared to use effectively. If the technology is underutilized, poorly integrated, unsupported, or difficult to explain to patients, the lower upfront price may not translate into better long-term value. In fact, this bare-bones approach can contribute to missed outcomes, inconsistent use, and a device that never becomes a meaningful part of patient care.
A stronger evaluation weighs price alongside the practical realities of implementation.
A strong partner will want to help you think through the clinical, operational, educational, and economic realities of adoption before you buy. The wrong partner may have little interest in that nuance, focusing instead on pushing the cheapest possible solution out the door.
Shockwave systems can vary widely in cost, and it is natural for medical professionals to compare pricing as part of the buying process. But even beyond the risks outlined above, focusing on the cheapest option is limiting for a very simple reason: price alone is a poor predictor of value.
That is especially true in a market where many companies have added “wave” to a product name and positioned themselves within the broader Shockwave category. Validated Shockwave devices are backed by 30+ years of clinical evidence, but these imitator devices may lack the same level of published research supporting their use.
A superficial, quick-scan side-by-side price comparison can be misleading. Why? Because it only captures the most obvious first-order costs. For example:
ROI depends on what happens once the technology is inside your practice: how often it is used, how confidently it is applied, how well patients understand it, and whether it becomes part of your clinical model rather than an occasional add-on.
All of these factors show why the better question is not only, “What does it cost?” It is, “What will it take for this to become a meaningful part of my practice?” and “How will this help me best help my patients?”
Many Shockwave purchases fall short not because the practice chose to invest, but because the post-purchase implementation never fully takes shape. The device arrives, the team receives some initial instruction, and then real-world adoption depends on dozens of practical details that are easy to underestimate.
Important inflection points when implementing Shockwave include:
In short, the practices that want to achieve the greatest possible ROI on their investment will not treat Shockwave as a simple plug-and-play modality. Using Shockwave is not rocket science, but there is a real proficiency curve to fully integrating Shockwave into your continuum of care.
That is why the purchase is only the starting point. Long-term success depends on practical post-sale support: ongoing education, protocol refinement, real-world application guidance, and peer connection with providers who are actively using Shockwave in patient care.
Learn more about how to incorporate Shockwave into a regenerative medicine practice.
The implementation nuances outlined above show why who you purchase from matters as much as the device itself. By this point in the buying process, the question is no longer just whether a device can deliver Shockwave. The more important question is whether the provider can help your practice keep progressing after the system is installed: from basic use, to consistent protocols, to broader clinical confidence.
Initial training can show your team how to operate the device. It cannot, by itself, teach a practice how to keep expanding appropriate use, refine technique across different conditions, or build Shockwave into a mature treatment strategy.
Look for a partner that supports learning beyond onboarding. That means ongoing education opportunities, structured clinical resources, and guidance that helps your team evolve protocols as confidence grows.
Without that continued development, Shockwave often stays limited to the first few indications a provider feels comfortable treating. With the right educational support, practices are better positioned to expand usage thoughtfully and apply the technology with greater consistency over time.
Shockwave is not a static modality. The research, treatment applications, and clinical protocols continue to evolve, which means practices need more than a device manual and a few starter indications.
A strong partner should help you stay connected to that evolution. That includes sharing relevant research, explaining how new evidence may apply in practice, and helping translate clinical developments into usable treatment strategies. The value is not simply knowing that more studies exist. It is understanding what the evidence may mean for patient selection, protocol development, multimodal care, and expanded use over time.
This is part of how practices move beyond treating one familiar condition with one device. With the right educational support and peer connection, providers can build confidence across a broader range of MSK and regenerative applications while staying grounded in research-supported use cases.
Many experienced Shockwave users are not thinking in terms of a single device for a single condition. They are thinking about how different energy-based technologies can work together as part of a broader treatment strategy, especially for complex or chronic musculoskeletal conditions.
A knowledgeable partner should be able to help you understand how Radial Pressure Wave, Focused Shockwave, and Extracorporeal Magnetotransduction Therapy (EMTT) may fit together in practice. That includes identifying which use cases make sense for your patient population, how treatments may be sequenced, which patient profiles may benefit from a combined approach, and what evidence supports those decisions.
The goal is to build a clear clinical strategy around:
Learn more about how to integrate an optimal combined EMTT-Shockwave approach.
Materials and training resources are useful, but some of the most valuable learning comes from experienced medical professionals who are actively using Shockwave in patient care. Those conversations can surface the practical details that do not always fit neatly into a protocol document: how providers think through difficult cases, adjust techniques, sequence treatments, and avoid common pitfalls.
Look for a partner that can connect you with clinicians and thought leaders who are already applying Shockwave at a high level. Access to case discussion, real-world insights, advanced techniques, and both U.S. and international leaders in the field can shorten the learning curve and help your practice keep improving as your experience grows.
One of the most valuable parts of a strong Shockwave partnership is access to other providers who are working through similar clinical and operational questions. Customer support can help resolve a specific issue. A clinical community can help providers keep learning, compare real-world experiences, and refine how the technology is used over time.
Look for a partner that provides access to:
For example, CuraMedix offers the CuraMedix Insiders’ Exchange, a private, community-based education platform for providers who have invested in STORZ Medical Shockwave and EMTT devices directly from CuraMedix. The platform includes protocol resources, application guides, videos, quick tables, on-demand webinars, live and recorded courses, discussion forums, patient-facing marketing materials, technical resources, troubleshooting tips, maintenance support, and opportunities for providers to ask questions and share best practices.
That kind of community matters because you are not learning in isolation. Providers can gain confidence faster, keep refining their approach, and learn from others who are actively applying the technology in patient care. The difference between stagnation and growth is often who you are learning alongside.
All of these partner qualities ladder up to one core outcome: consistent, confident use of the technology. The real risk is not only choosing the wrong system. It is investing in a capable system and never fully using what it can do.
A high-value partner helps your practice keep moving after the initial purchase. That means support that is tied to utilization, not just troubleshooting. As your team gains experience, the right partner should help you:
This depth of support helps prevent Shockwave from becoming a narrowly used device in the corner of the practice. Instead, it supports the larger goal: making the technology a practical, trusted, and sustainable part of patient care.
Ready to compare Shockwave options for your practice? CuraMedix can help you evaluate the technology, clinical applications, implementation considerations, and long-term support behind the purchase.
As the leading U.S. distributor of STORZ Medical technology, CuraMedix offers a complete suite of Radial Pressure Wave, Focused Shockwave, and Extracorporeal Magnetotransduction Therapy (EMTT® ) devices for medical professionals looking to expand non-invasive treatment options. Our team supports practices with education, training, service, and practical guidance designed to help turn device adoption into confident clinical use.
Reach out to CuraMedix to discuss your goals, compare technology options, and learn which Shockwave solution may be the right fit for your practice.